Jade Biosciences (NASDAQ:JBIO) Stock Jumps 5% – Here’s Why

Jade Biosciences, Inc. (NASDAQ:JBIO)’s share price rose 5% on Wednesday. The company traded as high as $13.87 and last traded at $14.0850. Approximately 271,847 shares were traded during trading, a decline of 64% from the average session volume of 749,033 shares. The stock had previously closed at $13.41.

Analysts Set New Price Targets

A number of research firms recently commented on JBIO. Wedbush reissued an “outperform” rating and set a $47.00 target price on shares of Jade Biosciences in a research report on Thursday, October 1st. Wall Street Zen downgraded Jade Biosciences from a “sell” rating to a “strong sell” rating in a research report on Saturday, September 12th. BTIG Research raised their price objective on Jade Biosciences from $74.00 to $77.00 and gave the stock a “buy” rating in a research note on Monday, August 10th. HC Wainwright reissued a “buy” rating and set a $55.00 price target on shares of Jade Biosciences in a research report on Thursday, October 1st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Jade Biosciences in a report on Friday, September 11th. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Jade Biosciences currently has an average rating of “Moderate Buy” and a consensus target price of $51.75.

Jade Biosciences Stock Up 5.3%

The stock’s 50-day moving average price is $19.21 and its 200 day moving average price is $19.74. The firm has a market capitalization of $897.99 million, a price-to-earnings ratio of -7.34 and a beta of 1.64.

Jade Biosciences (NASDAQ:JBIO) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.10). On average, sell-side analysts anticipate that Jade Biosciences, Inc. will post -2.89 earnings per share for the current year.

Institutional Trading of Jade Biosciences

Several institutional investors have recently added to or reduced their stakes in the stock. Y Intercept Hong Kong Ltd acquired a new stake in shares of Jade Biosciences in the first quarter valued at $353,000. Quantinno Capital Management LP raised its stake in shares of Jade Biosciences by 3.6% in the first quarter. Quantinno Capital Management LP now owns 30,551 shares of the company’s stock valued at $429,000 after acquiring an additional 1,059 shares in the last quarter. Engineers Gate Manager LP acquired a new position in Jade Biosciences during the 2nd quarter worth $503,000. Bank of America Corp DE boosted its stake in shares of Jade Biosciences by 2.9% in the 1st quarter. Bank of America Corp DE now owns 38,598 shares of the company’s stock valued at $542,000 after buying an additional 1,086 shares during the period. Finally, 9823 Capital L.P. acquired a new stake in Jade Biosciences in the fourth quarter valued at approximately $821,000.

Jade Biosciences Company Profile

Jade Biosciences, Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune and inflammatory diseases. The company’s research and development efforts are directed toward antibody-based medicines designed to address significant unmet needs in immune-mediated conditions.

Jade’s pipeline includes investigational therapeutic programs intended to modulate biological pathways involved in inflammation and immune-system activity. As a development-stage company, its products remain subject to clinical testing and regulatory review, and there is no assurance that any candidate will receive approval or reach the commercial market.

The company is headquartered in the United States and is developing its portfolio for potential use in global markets.